Nuvectis Pharma (NVCT) Institutional Ownership $5.49 +0.03 (+0.55%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Nuvectis Pharma (NASDAQ:NVCT)CurrentInstitutional OwnershipPercentage96.77%Number ofInstitutional Buyers(last 12 months)12TotalInstitutional Inflows(last 12 months)$1.29MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$102.55K Get NVCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Nuvectis Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NVCT Institutional Buying and Selling by Quarter Nuvectis Pharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/16/2024Geode Capital Management LLC79,716$501K0.0%+49.8%0.413% 11/5/2024GSA Capital Partners LLP50,129$315K0.0%+3.7%0.269% 11/5/2024Nations Financial Group Inc. IA ADV10,000$63K0.0%N/A0.054% 10/25/2024Iridian Asset Management LLC CT55,380$348K0.1%N/A0.297% 9/16/2024Point72 Asia Singapore Pte. Ltd.9,203$58K0.0%N/A0.050% 8/15/2024Point72 Asia Singapore Pte. Ltd.9,203$58K0.0%N/A0.050% 8/14/2024Marshall Wace LLP33,868$214K0.0%-32.4%0.185% 8/9/2024Renaissance Technologies LLC74,500$472K0.0%+20.7%0.406% 7/16/2024Baxter Bros Inc.12,500$79K0.0%N/A0.068% 7/12/2024Baldwin Brothers LLC MA168,630$1.07M0.1%+9.4%0.918% Get the Latest News and Ratings for NVCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. 5/10/2024Vanguard Group Inc.298,800$2.45M0.0%+1.5%1.626% 4/18/2024Blue Zone Wealth Advisors LLC14,350$118K0.0%N/A0.081% 2/12/2024Edmond DE Rothschild Holding S.A.19,170$160K0.0%N/A0.111% 1/30/2024Strs Ohio6,200$51K0.0%+59.0%0.036% 1/8/2024Baldwin Brothers LLC MA142,040$1.19M0.1%+22.0%0.820% 11/2/2023Forbes J M & Co. LLP34,000$438K0.1%-49.3%0.197% 10/26/2023Strs Ohio3,900$50K0.0%+178.6%0.023% 10/10/2023Baldwin Brothers LLC MA116,380$1.50M0.1%+29.2%0.675% 8/10/2023Hollencrest Capital Management3,040$49K0.0%N/A0.019% 8/4/2023American International Group Inc.3,298$53K0.0%N/A0.021% 8/3/2023Forbes J M & Co. LLP67,000$1.07M0.1%N/A0.418% 8/2/2023Bank of Montreal Can11,012$200K0.0%N/A0.069% 7/14/2023Baldwin Brothers LLC MA90,061$1.44M0.1%-37.4%0.563% 5/11/2023Edmond DE Rothschild Holding S.A.24,570$322K0.0%N/A0.167% 4/21/2023Baldwin Brothers LLC MA143,800$1.89M0.2%+7.9%0.975% 11/4/2022Ronit Capital LLP562,547$3.99M5.4%+34.2%3.843% 10/14/2022Baldwin Brothers LLC MA133,000$943K0.1%+9.9%0.908% 8/4/2022Ronit Capital LLP419,282$4.70M6.7%-23.8%3.297% 7/18/2022Baldwin Brothers LLC MA121,000$1.36M0.2%N/A0.951% 5/11/2022Ronit Capital LLP550,000$4.08M5.1%N/A4.325% (Data available from 1/1/2016 forward) NVCT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NVCT shares? During the previous two years, 17 institutional investors and hedge funds held shares of Nuvectis Pharma. The most heavily invested institutionals were Vanguard Group Inc. ($2.45M), Baldwin Brothers LLC MA ($1.07M), Geode Capital Management LLC ($501K), Renaissance Technologies LLC ($472K), Forbes J M & Co. LLP ($438K), Iridian Asset Management LLC CT ($348K), and GSA Capital Partners LLP ($315K).Learn more on NVCT's institutional investors. What percentage of Nuvectis Pharma stock is owned by institutional investors? 96.77% of Nuvectis Pharma stock is owned by institutional investors. Learn more on NVCT's institutional investor holdings. Which institutional investors have been buying Nuvectis Pharma stock? Of the 16 institutional investors that purchased Nuvectis Pharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Baldwin Brothers LLC MA ($76.98K), Forbes J M & Co. LLP ($67K), Iridian Asset Management LLC CT ($55.38K), Edmond DE Rothschild Holding S.A. ($43.74K), Geode Capital Management LLC ($26.49K), Point72 Asia Singapore Pte. Ltd. ($18.41K), and Blue Zone Wealth Advisors LLC ($14.35K). How much institutional buying is happening at Nuvectis Pharma? Institutional investors have bought a total of 366,101 shares in the last 24 months. This purchase volume represents approximately $3.68M in transactions. Which Nuvectis Pharma major shareholders have been selling company stock? The following institutional investors have sold Nuvectis Pharma stock in the last 24 months: Baldwin Brothers LLC MA ($53.74K), Forbes J M & Co. LLP ($33K), and Marshall Wace LLP ($16.20K). How much institutional selling is happening at Nuvectis Pharma? Institutional investors have sold a total of 102,939 shares in the last 24 months. This volume of shares sold represents approximately $1.39M in transactions. Related Companies ANAB Major Shareholders GHRS Major Shareholders SIGA Major Shareholders TKNO Major Shareholders ZVRA Major Shareholders ATXS Major Shareholders PRTC Major Shareholders MBX Major Shareholders CYRX Major Shareholders KMDA Major Shareholders This page (NASDAQ:NVCT) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
